Article Text

Download PDFPDF
Timing the initiation of treatment in Parkinson’s disease
  1. Donald G Grosset1,
  2. Anthony H Schapira2
  1. 1
    Institute of Neurological Sciences, Southern General Hospital, Glasgow, UK
  2. 2
    University Department of Clinical Neurosciences, Royal Free and University College Medical School, University College London, London, UK
  1. Dr Donald G Grosset, Institute of Neurological Sciences, Department of Neurology, 3rd Floor above Ward 68, Southern General Hospital, 1345 Govan Rd, Glasgow G51 4TF, UK; d.grosset{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

It is estimated that the dopaminergic neuronal loss that causes the characteristic motor features of Parkinson’s disease (PD) has reached 50–70% by diagnosis and it is progressive. Clinical, imaging and pathological studies suggest that the cell loss begins 7–10 years before the onset of clinical features sufficient to allow the diagnosis of PD. During this period of pre-diagnostic neurodegeneration, compensatory mechanisms are developed to maintain normal basal ganglia function.1 Eventually, these fail and symptoms emerge, enabling a diagnosis which is usually based on the combination of bradykinesia, rigidity and tremor. The delay from symptom onset to diagnosis is variable and …

View Full Text


  • Competing interests: None.

Linked Articles